新型镇静药瑞马唑仑的临床研究进展  

Progress on the clinical study of the new sedative remimazolam

作　　者：谌天奇 李香洁 尹杏杏 张永明 SHEN Tianqi;LI Xiangjie;YIN Xingxing;ZHANG Yongming(Department of Anesthesiology,No.984 Hospital of Joint Logistics Force,Beijing 100094,China)

机构地区：[1]联勤保障部队第九八四医院麻醉科,北京100094

出　　处：《世界临床药物》2022年第11期1511-1515,共5页World Clinical Drug

摘　　要：瑞马唑仑(remimazolam)是一种新型短效苯二氮[艹卓]类药物,作用于γ氨基丁酸受体。瑞马唑仑通过组织酯酶快速水解为无活性的羧酸代谢物,代谢不依赖肝肾功能,半衰期短且不受输注时长影响,长时间输注不易发生蓄积并可以被氟马西尼(fumazenil)拮抗,对血流动力学和呼吸影响较轻。这些特点使得瑞马唑仑成为较理想的镇静药物,近些年临床上开始应用于无痛诊疗、重症监护室的镇静以及全身麻醉的诱导和维持,是一种应用前景广阔的镇静药物。现就瑞马唑仑的作用机制、药代动力学、对器官功能的影响及临床应用研究进展进行综述,以为其临床应用提供理论依据。Remimazolam is a new ultrashort-acting benzodiazepine that acts on the γ-aminobutyric acid receptor.Remimazolam is rapidly hydrolyzed into inactive carboxylic acid metabolite by esterase metabolism, and its metabolism is independent on liver and kidney function. It has a short half-life and is not affected by the infusion time. Long time infusion is not easy to accumulate and can be antagonized by fumazenil, which has less impact on hemodynamics and respiration.These characteristics make remimazolam an ideal sedative drug. In recent years, it has been used in painless diagnosis and treatment, sedation of ICU, and the induction and maintenance of general anesthesia, the prospects of application are board.This paper mainly reviews the mechanism of action, pharmacokinetics, the infuence on organ function, and the research progress of clinical application, so as to provide a theoretical basis for its clinical application.

关 键 词：瑞马唑仑 苯二氮[艹卓]类药物 γ氨基丁酸受体 

分 类 号：R971.3[医药卫生—药品]